Get started

Vaccines

💉 Pfizer, Inc. Goes Bearish | 44, 39 and 34 Coming NextThe PFE stock, Pfizer, Inc., looks like is about to take a deep dive... Going red... Let's have a look! The most obvious signal is the weekly candle today moving below EMA50, telling us that this stock is preparing to drop for months. Pfizer, Inc. peaked December 2021. In mid-December 2022 PFE printed the inverted hammer bearish candlestick pattern or shooting star. This candlestick came at a long-term lower high (Dec. 2022 vs Dec. 2021). Trading volume has been decreasing since November 2020. The RSI has moved below 50, now bearish, and is trending down strong. The next and at the same time critical support level is 48.24. If this level breaks, PFE is going to move to 39.91 as a new low with even lower possible, but this level is the main one. Bearish target of 39.91 at 0.618 Fib. retracement level followed by 0.786 or 33.98. There is something going on at Twitter as well... I don't know... Do your own research... Not only about trading but also about your health. Thank you for reading. Namaste.
NYSE:PFEShort
by AlanSantana
1
Sanofi S.A. (SAN.pa) bearish scenario:The technical figure Channel Up can be found in the daily chart in the French company Sanofi S.A. (SAN.pa). Sanofi S.A. is a French multinational pharmaceutical and healthcare company. Sanofi engages in the research and development, manufacturing and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines (it is the world's largest producer of the last through its subsidiary Sanofi Pasteur). The Channel Up broke through the support line on 24/01/2023. If the price holds below this level, you can have a possible bearish price movement with a forecast for the next 26 days towards 86.54 EUR. According to experts, your stop-loss order should be placed at 92.90 EUR if you decide to enter this position. French drugmaker Sanofi SA plans to launch a drug for rare bleeding disorder hemophilia A this year, Chief Executive Officer Paul Hudson told CNBC in an interview last week. The U.S. Food and Drug Administration last year accepted the marketing application for the therapy, which is being developed in collaboration with Swedish drugmaker Sobi, and is expected to decide on an approval status by Feb. 28. Hemophilia A is an inherited bleeding disorder in which the blood does not clot normally. About 400 babies are born with this condition every year, although the exact number of people affected is not known, according to government data. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
EURONEXT:SANShort
by legacyFXofficial
$XLV:$KRE: Deflation winners and losersWe're seeing value health care ($XLV) show a lot of relative strength against other sectors as the dollar has been pushing. ($KRE) is often tied to growth when compared to it's bigger brother ($XLF) and eventhough financials do tend to benefit from rising rates, this has been much more of a hard landing and the financial rotation many expect may not come to pass, instead look for $XLV to continue soaking up 2022 when compared to other sectors.
AMEX:XLVLong
by Fox_Technicals
MicroStrategy buys the dip by purchasing 660 Bitcoin for $25MMicroStrategy bought significantly less BTC in January than in previous months, according to official data. Major Bitcoin (BTC) investor ​​MicroStrategy has announced another major BTC purchase during a market dip to collect a total of 125,051 BTC as of Monday. According to an official form with the United States Securities and Exchange Commission (SEC) filed on Tuesday, ​​MicroStrategy purchased 660 BTC between December 30, 2021, and January 31, 2022, for “approximately $25 million” in cash. The average BTC price of the purchase amounted to $37,865 per BTC, including fees and expenses, the report notes. As of Jan. 31, MicroStrategy held about $3.78 billion worth of BTC at the average purchase price of approximately $30,200 per BTC, inclusive of fees and expenses. The latest report comes shortly after the SEC reportedly rejected MicroStrategy’s Bitcoin accounting practices, causing MicroStrategy shares to plummet in mid-January. The SEC specifically objected to MicroStrategy reporting data related to BTC purchases based on non-Generally Accepted Accounting Principles (GAAP). The authority argued that MicroStrategy used non-GAAP methods of calculating figures for its BTC buys excluding the “impact of share-based compensation expense and impairment losses and gains on sale from intangible assets.” The latest Bitcoin buy is apparently not that big compared to the most recent BTC purchases by MicroStrategy. In December 2021, MicroStrategy announced two major BTC purchases, buying 1,434 BTC from Nov. 29 to Dec. 9 at the average price of $57,477 per BTC and then purchasing 1,914 BTC from Dec. 9 to Dec. 29 at the average price of $49,229 per BTC. Previously, the company had bought as much as 7,002 BTC from Oct. 1 to Nov. 29 at the average price of $59,187 per BTC. Related: MicroStrategy CEO won’t sell $5B BTC stash despite crypto winter Major Bitcoin investors including the government of El Salvador continued to investi in BTC amid a market downturn in January. On Jan. 21, El Salvador president Nayib Bukele announced that the Salvadoran state purchased 410 BTC for $15 million, placing the average price at approximately $36,585 per BTC.
BITSTAMP:BTCUSD
by monicaagrizzi9
$BNTX^ $BNTX will announce if its possible to revise their current vaccine to accommodate the new strain in 2 weeks and could redesign its vaccine within 6 weeks, with an aim to distribute it within 100 days. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
NASDAQ:BNTXLong
by BADQOMOCAWGOWLD
1
$MRNAModerna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, Metagenomi, Inc., and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd.; Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group; Aldevron, LLC; Institute for Life Changing Medicines; and AbCellera Biologics Inc. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
NASDAQ:MRNALong
by BADQOMOCAWGOWLD
Novavax ShortPfizer's monopoly is very strong on the Covid-19 vaccines . They are spending millions hiding their side effects and creating hurdles for their competitors at the regulatory agencies SUCCESSFULLY . It maybe that Novavax has one the best products out there but that simply does not matter at this point , we know how powerful big pharma can be and Novavax's lateness to the game will not serve them well here . The biggest dangers to NVAX are now the regulatory agencies taking long/asking for additional info and the COVID-19 Antiviral drug news ( Merck's pill approval will be this months and Pfizer may come out with their Phase III study result any moment now). Both are very likely . NVAX will likely reject braking $200 TODAY. $195 -$200 will be a great entry point for a opening a short position on this . RISK /REWARD RATIO VERY LUCRATIVE .
NASDAQ:NVAXShort
by Bobpnmicro
4
I'm buying weakness in Chilean stocksAfter the IPCC's recent report showing that the North Atlantic Current may be on its last legs, I decided that I needed to diversify away from the US and Europe a bit. (If the North Atlantic Current fails, it would cause massive, disruptive climate change for Europe and North America.) So I committed to look for opportunities in some country ETFs. The one I've been buying is $ECH, the iShares Chile ETF. Chile stocks are beaten down because of currency weakness amid heavy pandemic spending, but honestly their debt-to-GDP ratio is still one of the world's best at just 27%. (Contrast the US at 107% and Japan at 238%.) Chile has had a highly effective vaccine rollout, with the world's sixth highest vaccination rate. (With 67.2% of Chileans fully vaccinated, they lag behind a few much smaller countries, like Malta and Iceland.) Thanks to pandemic UBI and a high vaccination rate, Fitch yesterday raised its 2021 real GDP growth forecast for Chile from 6.1% to 8.3%, making Chile one of the world's fastest growing economies this year, trailing just behind China's 8.4%. But whereas China ETFs trade at 14x cash flow and yield 1.1%, $ECH trades at less than 5x cash flow with a distribution yield of 2.34%. There is, undoubtedly, some political risk when buying a Latin American ETF. Latin America is notorious for its political instability, and Chile is no exception. Chile currently ranks 19th in the world for economic freedom, and its current leader is a Harvard-trained economist and business engineer. But he's also wildly unpopular due to excessive use of force against protesters the last couple years. The country is currently in the process of drafting a new national constitution, and many of the constitutional delegates lean left. It remains to be seen what shape the future government of Chile might take. Despite the uncertainty, the immediate future for Chile looks relatively bright. At this valuation and with this GDP growth rate, I've bought a modest stake and plan to hold for the forseeable future.
CBOE:ECHLong
by ChristopherCarrollSmith
4
Pfizer here we go! Holding while price is green. 🚀🚀🚀Stocks trend. A lot. Much more than Forex. Pfizer is going parabolic while breaking all time high and $50, this could be the start of a big trend, or it might not. Let's look at a few examples starting with Pfizer. Clearly we see how with stocks we can make big multiples of our risk. Like 25R in stocks versus 10R in Forex (for example, reality is probably close to that) Zooming in the little impulses: I don't know how many "casuals" are interested in Pfizer, but it is a word billions of people know. We can look at Tesla & PonziStop: How about another one just to illustrate? So the question is, how to hold on but without giving back all profits? 1 solution is sell half once a stop is reached keep half with a much wider stop. Smooths out the PnL. And this is probably what I'll do. On a longer TF I'd look to add, here this is all a short term play, expecting the stock to go parabolic. I am at exactly 5 times my risk (counting spreads) as of writting this. Hasn't even been 2 weeks yet. Talk about a monster. This risk a monster correction too. Hopefully it warns before.
NYSE:PFELong
by MrRenev
4
HALBERD CORPORATION· Current Price – $0.0419 · Best Case Scenario PT over 1$ · Market Cap – $11 million · Debt – 0 Halbert Corporation Are a biomedical company with a clear aim to revolutionize the world of medicine. They are working towards a creation of variety of antibodies and treatments using extracorporeal techniques (outside of body). They believe they have the technology to cure diseases like, Covid-19, PTSD, Cancer, CTE, tuberculosis, malaria, strokes and heart attacks, blood sepsis, Alzheimer’s Disease. In the last 8 months they have secured 7 provisional patents (which give the global rights) to technology of treating severe Covid-19 patients, Covid-19 nasal spray, antibody cocktail to boost immune system against Covid - 19 and recently developed two new antibodies that no other big pharma has, which allows them detect Covid-19 in matter of minutes using saliva or blood samples. Furthermore, are working with $GRPS to develop anti-addiction patches (alcohol, drugs, nicotine). To achieve their further goals they have carefully selected to partner with Arizona State University (who have won the first place in innovation for the last 6 years going in the USA, higher than MIT or Stanford). This partnership has already delivered amazing milestones and they are already working towards filing for new joint provisional patents. Halbert has 0 debt, yes ZERO and been receiving funding in 2 million chunk donations due to promising results. Halberd’s corporate charter also prohibits them from issuing any kind of convertible financial instrument, debt or preferred stock, however the corporation shall be able to issue warrants or options. Management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment. Furthermore, the ultimate catalyst, which seems quite likely is for Halbert to partner or licence their technology to one of the big pharma as the CEO, William has mentioned so on multiple occasions. In the past, he has been approached by the big pharma (Pfizer and Novartis), and hopes the same will happen with their revolutionary technology. Issued Patents 2014 - Sequential Extracorporeal Treatment of Bodily Fluids 2015 - Utilization of Stents for the Treatment of Blood Borne Carcinomas Provisional Patents 11/2020 - Fluorescent Antibody’s in Covid-19 Detection & Treatment 10/2020 - Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus). 10/2020 - Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus 09/2020 - Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans 04/2020 - Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus 04/2020 - Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients 03/2020 - Method for Treating and Curing Covid-19 Infection Future Patents During podcasts and interviews the CEO said he will announce another 2 patents soon. They are waiting to achieve provisional status to ensure the technology is safe. Further patents are in the pipeline as CEO’s devised a strategy to secure as many patents as they can, of which they could then either licence or partner on developing on joint ventures with big pharma. Upcoming Catalyst 2021 · 2 patent provisional applications yet to be announced · Development of antibody cocktail vitamins to boost immune system against Covid-19 (Q2 launch and start to generate revenue) · Development of Covid-19 Nasal Spray · Commercial development of Covid-19 test using saliva or blood (takes only a minute no nasal swap which is uncomfortable) · Patent Licencing to other pharma companies – they produced antibodies that are stronger than some of the big pharma · Partnerships and joint ventures with other organizations · Discovery of new treatments and patent fillings · Further development of extracorporeal technology to treat cancer, PTSD, Alzheimer’s, blood sepsis, CTE · Anti-addiction patches Sociability Factor In penny stock market, especially during current times (rise of social media and social traders) the CEO’s or the organization being sociable, sharing achievements, milestones, ethos and so on can have a massive impact on the share value. In this regard, Halberd’s corporation in my view would score high points. They tend to release anywhere between 2/5 press releases a month in which various milestones would be announced via text, video interviews or podcasts. Senior Leadership Team The CEO’s aim was to ensure that they develop a very cohesive team of talented people to achieve greatness. Here below I have listed a few KEY members including bio snapshots. Business Advisory Board The CEO – based on the videos and podcasts that are available (6+) of William A. Hartman sounds very ambitious and driven on a mission to be the best in the industry and revolutionize medicine. He believes Halberd corporation share value should be worth $1 per share. This may sound like very ambitious venture for some, however, let us not forget he founded and headed separate business group within TRW Automotive with plants in the U.S., Mexico and Europe that produced combined annual sales of $1.3 Billion – this shows extreme capability. He has also worked as COO for Nanologix, Inc, President and CEO of Premier Biomedical. I would recommend checking out any of his interviews to feel his passion. Carl Eller - retired NFL Pro Football Hall of Famer, and President of the NFL Retired Players Association, was drafted in 1964 as the league’s 6th pick overall by the Minnesota Vikings, he became a major factor as a defensive end with the unit known as the “Purple People Eaters.” Eller became a six-time Pro Bowl player who appeared in four Superbowls and is currently focused on helping former players transition into retirement. Alec Torelli - is an entrepreneur, author, motivational speaker and professional poker player who has worked with various companies to apply his life experiences/lessons from poker, in a practical manner, to carry out their corporate visions, increase sales and/or improve service delivery while creating meaningful lives for their employees. Scientific Advisory Board Mitchell S. Felder, MD - is a prolific inventor. He is a Board Certified Neurologist and former CEO, President, Chairman and founder of Infectech and Nanologix, and currently serves as Locum Tenens Attending Neurologist with UPMC Pennsylvania Dr. Felder has authored or co-authored six publications, three studies and has currently 21 issued patents. Dr. Felder was the Acting Chief of the Department of Neurology, Sharon Regional Health System from 1989 until 2001. Dr. Felder served as the Acting Chief of the Department of Neurology at the William Beaumont Army Medical Center in 2011. Dr. Qiang (Shawn) Chen, who is the Principal Investigator at ASU, in charge of the research and development for Halberd Corp: Take a look at his research projects over the last 4-5 years and you see why this HALB/ASU cooperation is a marriage made in heaven. Only weeks ago, Halberd signed another R&D-agreement with GreenBioAZ inc, it's a start up from Arizona State University and will do research for Halberd's radiofrequency technology. Dr. Chen is CEO of GreenBioAZ Patricio Reyes, MD, FAAN - a board certified neurologist and neuropathologist, and Chief of Neurology/TBI/Alzheimer’s Disease/Cognitive Disorders at the VA Medical Center in Phoenix, Arizona and is a Board Member of the Retired National Football League Players Association. Dr. Reyes is a board member, and former Chair of the Education Committee and 2009 Distinguished Educator of the Association of Ringside Physicians. HALB has access to the VA Hospital Group because of Dr. Reyes. Timeline of Key Press Releases I have gone through the list of all of their press releases (they post regularly) and compiled key updates here below: April 6, 2020 - Halberd announces agreement to retire 192,000,000 outstanding common shares and reduced authorized shares of common stock to 1,000,000,000. April 8, 2020 – Halberd, Premier Biomedical ($BIEI) and Gold River Productions ($GRPS) announce the signing of a multi-faceted agreement for ongoing R&D into a potential treatment and cure for Covid-19 as well as development of Premier’s Anti-Addiction Patch. July 1, 2020 - Halberd establishes United Kingdom subsidiary to facilitate access to European research facilities and markets to establish a global footprint. July 13, 2020 - Halberd’s corporate charter prohibits it from issuing any kind of convertible financial instrument, debt, or preferred stock. August 4, 2020 - Halberd secures $2 Million for Covid-19 Research August 31, 2020 - Halberd signed an agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments. September 21, 2020 - Covid-19 Research Program Progress – Successful Covid Spike Protein Disease Antigen September 24, 2020 - Successful creation of a fluorescent antibody, that will help them create a rapid Covid-19 test using saliva or a drop of blood. This approach will allow for accurate test results in a matter of minutes – believe travel industry may benefit from this approach. October 8th, 2020 – CEO’s letter of updates and accomplishments October 13, 2020 – Halberd and ASU Develop Antibody Against Covid-19, pursuing new joint patent. October 19, 2020 – in process to filing a new joint patent with AUS for creation of a new class of anti-Spike protein monoclonal antibodies against Covid-19. This protein will allow extremely rapid identification of the Covid-19 virus in nasal mucus, saliva, and blood. October 29, 2020 – Strategic plan curing blood sepsis, Alzheimer’s Disease, Heart Attack and Stroke using extracorporeal process November 12, 2020 – Patent pending for Covid-19 detection test from saliva or blood in minutes. December 1, 2020 – Halberd re-organizes advisory board. December 17, 2020 - Halberd Corporation Pursues Extracorporeal Radio Frequency Treatment Against Covid-19 December 23, 2020 - Halberd Produces a Second Monoclonal Antibody Against Covid-19 Spike Protein – “Mathematically speaking, if each is 90% effective independently, then, absent any interrelationship of the two applications, the combination should be 99% effective. In other words, the prospect of obtaining diagnostic test false positives or false negatives is substantially reduced when antibodies work in tandem” January 4, 2021 - Halberd Corporation 2020 Year End CEO Letter, looking forward to 2021 January 14, 2021 - Halberd Develops Medication to Boost Immune System Against Covid-19 February 16, 2021 - Halberd has engaged GreenBioAZ to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate infectious disease. March 2, 2021 - Halberd’s 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater - “We are excited about the progress being made in developing Halberd’s effective proprietary antibodies against Covid-19. These results put our antibody in the same realm of effectiveness as the best-known competitive SARS-COV-2 antibodies. Since posting links may take an excessive amount of space here, you can find all the press releases here and search by date, plenty more to see that are not included in my post - Hope people found this helpful and I look forward to seeing what the future holds for $HALB!
OTC:HALBLong
by headdeveloper33
1
Global Quad 2I want to apologize for my lack of activity the past few months. A lot has changed in the markets and a lot has evolved in my approach to reading and navigating the markets. When it comes to my process, I have added the use of multiple lenses beginning first with a fundamental macro overlay called the GIP (Growth, Inflation, Policy) Quad Model, which give us 4 possible macroeconomic environments on a rate of change basis that we are in and could be headed towards. This model protected investors in advance of the 2020 crash with big positions in cash, bonds, and puts and it had its users in Gold and TLT from 3Q2018 until 3Q20. This model also has its users begin shorting USDs and buying commodities and Emerging markets beginning in May 2020. It is impossible to be perfect in markets and the model has made mistakes but overall it has convinced me it is a model worth using and paying attention to. Currently the GIP Model is showing the global economy already in Quad 2 and headed towards a Deep Quad 2 topping out by the 2nd quarter of 2021. Quad 2 is the macroeconomic environment where both economic growth and inflation are accelerating simultaneously. What many equity bears, bond bulls, and gold bulls are missing is that in 1Q20 the global economy hit rock bottom and there is only one direction out of an absolute rock bottom. Whether that's going sideways, a slow grind higher, or a better than expected recovery, all of those outcomes give us something that is better than what the economy was in the March of 2020. It is all about the Rate of Change, this is what the market cares about. Yes, we are in a recession, but the direction the economy is headed right now is different than the direction it was headed in at the start of 2020. On the Margin, a Biden-Kamala administration means: - Less trade war with both allies and foes. A move away from nationalism and isolationism. - Continued push for more stimulus - Giving the Federal Reserve the power to spend not just lend. Retail Central Bank accounts with digital currency stimulus checks etc.. - Possible stimulus directly from the executive branch - Republicans forget that Biden and Kamala are corporatists first and foremost and not nearly as far left as Fox news says. So, this means $DXY continues its downtrend, potentially hitting 80, 70, and maybe a new all-time low over the next 4 years. In the short-term, DXY's trend range is 91-88. Many Gold Bulls are confused why Gold and Silver haven't rallied to new highs despite DXY dropping to new lows, and the reason is because yields have risen alongside expectations for slightly better growth in 2021, higher growth expectations means investors will want to take on more risk in stocks and commodities over yield-sensitive safe havens like bonds and precious metals. AT THE SAME TIME, I still think silver miners and junior miners can do alright in Quad 2 even as the metals themselves stagnate because the amount of money the miners are making is pretty ridiculous. The miners that are well-positioned to expand production into an elevated gold price environment will have accelerating earnings which makes their stock attractive. An example of such a stock is $AUMN Golden Minerals. You really can't go wrong with anything in the commodities. Since the election energy, materials, and industrials have been great places to be. I think energy will continue to be a strong winner. That includes USOIL, Natural Gas, and Uranium. I think the agriculture complex can surprise to upside, including oranges, cocoa, coffee, and cattle. And the Covid losers, in general, will continue to outperform the Covid winners if yields continue to rise (study the US10Y) which is spurred by increases in expectations for future growth and inflation. This is why Copper has been smoking gold lately. Another way to play the steepening yield curve, is $IVOL, which is a low volatility and asymmetric way to play interest rates if you think bonds are overpriced. So to summarize: Bearish on bonds until Q2 of 2020, Bullish on global equities, Bearish on the US Dollar, Bearish on VIX, and on the margin bearish gold and neutral on silver, but bullish on some of the well-positioned gold and silver equities. Once this Quad 2 growth peaks in Q2, or maybe the model output pulls the probability forward of growth peaking in late Q1, whenever that point ends up being we will pivot towards being long gold and silver and shorting Chinese stocks, Oil, Russell 2000, Nasdaq, Financials, etc. but that will be later in 2021 with a Quad 3 or 4 environments (Quad 3 rising inflation falling growth, Quad 4 Falling inflation falling growth). Basically the bullish case is this: - Economy hit rock-bottom in March - Fed overshot monetary policy by a mile - Fiscal stimulus was like 10x the 2009 Fiscal stimulus - A lot more stim is on the way with Biden-Kamala - Biden-Kamala also means more global trade, less volatility in foreign policy - Travel restrictions become loosened as vaccine distributions take place - Highly unlikely that most of the USA and most of the world ever sees anymore covid shutdowns
TVC:US10YLong
by Ludwig_Von_Mises
IRRA ROAD MAPPOSSIBLE PATTERN : - BULLISH PENNANT -------------------------------- ※ DON'T FORGET TO USE TRAILING STOP 5% ※ ENTRY BUY: - BUY ON BREAK OUT: 1645 - ENTRY BUY AT RANGE PRICE OF 1615 - 1665 (OPTIONAL) (CLOSEST RESISTANCE TO BE BREAK IS AT 1685) --------------------------------------------------------------------------- ※ TARGET PROFIT 1: 1875 (FIBONACCI EXTERNAL RETRACEMENT 1 - 1.618) ※ TARGET PROFIT 2: 2100 (FIBONACCI EXTERNAL RETRACEMENT 1.618) ※ STOP LOSS: 1460 ------ DISCLAIMER ON ------
IDX:IRRA
by lalala_landzz